Natco Pharma declares interim dividend, reappoints key management
Natco Pharma declared a third interim dividend of ₹1.50 per share, with a record date of February 18, 2026. Key management, including the Chairman & MD and Vice Chairman & CEO, were re-appointed for one year from April 1, 2026. The company reported Q3FY26 consolidated revenue of ₹705.4 crore and net profit of ₹151.3 crore.
The re-appointment of key management and declaration of dividend are positive developments. The financial results show growth, which is a positive indicator for investors. The incorporation of a subsidiary is a strategic expansion.
The announcement includes the declaration of an interim dividend and the re-appointment of key management personnel, indicating stability and continued operations. The financial results show an increase in revenue and profit compared to the previous year.
Natco Pharma Limited announced the outcome of its Board Meeting held on February 12, 2026. The Board approved the unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31, 2025.
A third interim dividend of ₹1.50 per equity share for the financial year 2025-26 was declared, with a record date set for February 18, 2026, and payment commencing from February 26, 2026.
The Board also re-appointed Sri Venkaiah Chowdary Nannapaneni as Chairman & Managing Director, Sri Rajeev Nannapaneni as Vice Chairman & CEO, Sri Potluri Sivaramakrishna Prasad as Director and Executive Vice President (Corporate Engineering Services), and Dr. Donthineni Linga Rao as Director & President (Tech. Affairs), all for a period of one year effective April 1, 2026. These re-appointments are subject to shareholder approval via postal ballot.
Furthermore, the company noted the superannuation of its Chief Financial Officer, Mr. S. V. V. N. Appa Rao, effective February 12, 2026. Mr. Amit Parekh, Executive Vice President – Finance & Accounts, has been appointed as the new Chief Financial Officer effective February 13, 2026. Mr. Kalakuntla Srinivas Rao has been appointed as Executive Vice President – Pharma Division effective February 12, 2026.
The Board approved the incorporation of a wholly-owned subsidiary in Chile, NATCO Pharma Chile SPA, with an investment up to US$3,00,000 (₹2.50 crore). The Environmental, Social and Governance (ESG) Committee and Risk Management Committee have been reconstituted effective February 13, 2026.
The company reported consolidated total revenue of ₹705.4 crore for the quarter ended December 31, 2025, an increase from ₹651.1 crore in the same period last year. EBITDA stood at ₹216.8 crore with margins at 30.7%. Net profit after tax on a consolidated basis was ₹151.3 crore. The company also announced its intention to hold an earnings call on February 12, 2026, at 4 PM IST to discuss the results.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.